




## **FillerTest**

Predict the risk of filler complications



Fillers are safe, working with the best doctors and the best materials, but the patient's immune system also plays a very important role.



#### **FillerTest**

#### Determine patient's high or low predisposition to an immune reaction

**FillerTest** is an **immunogenetic test** intended to inform anyone considering filler treatments if they have a genetic predisposition that causes their immune system to overreact to fillers.

**FillerTest** informs if a patient has a high (positive) or low (negative) risk to a serious immune reaction to filler treatments.



#### FillerTest is highly recommended for patients that:



Have immune diseases, lot's of allergies, immune disorders or high general sensibility Have had complains and/or complications with fillers and/or other implants Want to start with fillers, do not have specific immune issues but are careful and worried about possible consequences Already have fillers and no complications (for some years), but are careful and worried

## Doctors identify and prevent serious complications from fillers when the result is confirmed:



#### **Negative test result - LOW RISK**

- Low risk of complications (< 2%)</li>
- Do not have the genetic predisposition
- · Can use fillers, considering normal low risk\*



#### **Positive test result - HIGH RISK**

- High risk of complications (>80%)
- Have the genetic predisposition
- Recommended NOT to use fillers
- Alternative treatments (i.e. Botox, PRP, facial laser, lipofilling, RF)

#### Positive result and already fillers?

- No further fillers
- Vigilance of immune reactions

|FillerTest Fagron Genomics

<sup>\*</sup> A negative result does not completely exclude the risk of complications, however the risk would be very low.

### FillerTest put safety first in your practice

predicting the risk of adverse reactions due to the patient's genetic condition



# Immunological knowledge of the patient to personalize a filler treatment



#### Who is recommended

- Patients with immune diseases, lots of allergies, immune disorders or high general sensibility.
- Patients that have suffered complications with fillers and/or other implants.
- Patients that want to start with fillers, do not have specific immune issues but are worried about possible complications.
- Patients with fillers and no complications, but are worried if complications could appear in the future.



#### The Research

The scientific research behind FillerTest showed a specific combination of two HLAs cause an increased risk for late onset immune mediate adverse reaction to foreign body implants. (Decates et al. 2020)



#### **Data privacy**

Fagron Genomics digital healthcare platform meets the requisite regulatory and data protection standards.

Preserving the patient from serious complications ensures confidence in the quality of the filler treatment and their trust in our practice.

|FillerTest Fagron Genomics

#### **FillerTest**

#### How it works

#### **Procedure**



DNA sample collection according to the instructions.



Registration of the kit and completion of the on-line questionnaire at www.fagrongenomics.com



The sample is sent to the laboratory by your doctor.



Results are provided in 4-5 weeks.

#### Kit content

- 1x Swab tube
- 2x Patient consent form
- 1x Instructions
- · 2x ID-labels
- 1x Biohazard bag
- 1x Shipping Courier bag



#### FillerTest Report

Once **questionnaire** is **complete** and genetic data available, **reports** can be **viewed and downloaded** from a **secure personal area**. Our digital healthcare platform **meets the requisite regulatory and data protection** standards.

#### References

- Decates T, de Wijs L, Nijsten T, Velthuis P. Numbers on injectable treatments in the Netherlands in 2016. J Eur Acad Dermatol Ve- nereol 2018 Aug;32(8):e328-e330.
- 2. Karim RB, Hage JJ, van Rozelaar L, Lange CA, Raaijmakers J (2006) Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases. J Plast Reconstr Aesthet Surg 59: 1409-1414.
- 3. Nelson L, Stewart KJ. (2011) Early and late complications of polyalkylimide gel (Bio-Alcamid®). J Plast Reconstr Aesthet Surg 64: 401-404.
- 4. Schelke LW, van den Elzen HJ, Canninga M, Neumann MH (2009) Complications after treatment with polyalkylimide. Dermatol Surg 35: 1625-1628.
- 5. Artzi O, Loizides C, Verner I, Landau M. (2016) Resistant and Recurrent Late Reaction to Hyaluronic Acid-Based Gel. Dermatol Surg. 42: 31-37.
- 6. https://data.epo.org/publication-server/pdf-document?pn=2564197&ki=B1&cc=EP; European patent "A METHOD FOR DETECTING THE SUSCEPTIBILITY TO DEVELOP ADVERSE SIDE EFFECTS RELATED TO BIOIMPLANTS".
- Decates TS, Velthuis PJ, Schelke LW, Lardy N, Palou E, Schwartz S, Bachour Y, Niessen FB, Nijsten T, Alijotas-Reig J. (2020) Increased risk of late-onset, immune-mediated, adverse reactions related to dermal fillers in patients bearing HLA-B\*08 and DRB1\*03 haplotypes. Dermatol Ther. 34: e14644.

|FillerTest Fagron Genomics

# LEGAL DISCLAIMER Fagron Genomics, S.L.U carries out genetic tests upon request by healthcare professionals, in relation to biological samples from patients obtained by the healthcare professional. Our tests do not replace a medical consultation, nor do they make up a diagnostic or treatment, nor should they be interpreted this way. Only healthcare professionals can interpret the results of said tests, based on their knowledge of the clinical records of the patients and other relevant factors and, under their responsibility, give a diagnostic or prescribe treatment to the patient. We decline all responsibility derived from the use and interpretation of the results of our tests by the solicitant healthcare professional.

Fagron Genomics, S.L.U expressly reserves any legal actions in case of an innapropiate, negligent or incorrect use or interpretation of the results of our tests. It is the responsibility of the healthcare professional who requests a test to guarantee to the patient the appropriate genetic advice as foreseen by Law 14/2007, of 3rd July, of biomedical research. As Fagron Genomics, S.L.U does not have access to the personal identifiable information about the patient from whom the sample comes, it is the responsibility of the requesting healthcare professional to comply with the applicable data protection Laws and regulations.

